Advanced Magnetics passed an important milestone earlier thismonth when the Food and Drug Administration issued a letter statingthat the new drug application for the company's Feridex MRI contrastagent is approvable. Advanced Magnetics, of Cambridge, MA,
Advanced Magnetics passed an important milestone earlier thismonth when the Food and Drug Administration issued a letter statingthat the new drug application for the company's Feridex MRI contrastagent is approvable. Advanced Magnetics, of Cambridge, MA, saidthat it is working with the FDA on final labeling for the agentas well as to resolve several questions relating to the NDA, whichwas filed in February 1994.
Feridex is an intravenous contrast agent designed to enhanceprimary and metastatic tumors in the liver on MRI scans. AdvancedMagnetics has licensed the agent to Berlex Laboratories in theU.S. and Canada (SCAN 2/15/95). Feridex is sold in Europe by Guerbetunder the trade name Endorem.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.